How Is Compounded Semaglutide Made?

Last reviewed: June 5, 2026

Last updated: June 5, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

Compounded semaglutide is prepared — not manufactured — by a state-licensed pharmacy, against a prescription written for an individual patient. That distinction is legal rather than semantic. Manufacturing produces standardised finished products under FDA-registered facility oversight; compounding under section 503A of the Federal Food, Drug, and Cosmetic Act produces a preparation for a specific patient and is exempt from certain requirements including FDA premarket approval. The FDA is explicit that compounded drugs are not FDA approved and that the agency does not review them for safety, effectiveness or quality before marketing.

The Regulatory Frame Determines Everything Else

Section 503A of the Federal Food, Drug, and Cosmetic Act covers traditional pharmacy compounding. A 503A pharmacy compounds pursuant to a valid prescription for an identified individual patient and is primarily regulated by its state board of pharmacy, with FDA oversight of certain conditions. Section 503B covers outsourcing facilities, a different category with different obligations. PlexusDx works only with licensed 503A compounding pharmacies.

Because compounded preparations are exempt from premarket approval, there is no FDA-reviewed prescribing information for a compounded semaglutide preparation. There is no approved label, no agency-reviewed adverse reaction table, and no post-marketing safety obligation identical to that of an approved product.

The FDA also draws a clear line between compounded drugs and generic drugs. Generics must establish therapeutic equivalence to a reference listed drug through an abbreviated application. No approved generic semaglutide exists, and a compounded preparation is not one.

Where the Active Ingredient Comes From

The active pharmaceutical ingredient must be obtained from a source meeting the requirements that apply to 503A compounding. The FDA has established an import alert covering GLP-1 active pharmaceutical ingredients with potential quality concerns, specifically to keep material manufactured without appropriate controls out of the U.S. supply chain.

That alert operates as a green list: it does not apply to API from manufacturers that, based on FDA inspection or evaluation, appear to comply with manufacturing practice standards, and it does not create new limits on lawful compounding of GLP-1 drugs.

Salt forms are a specific and important exclusion. The FDA states that semaglutide sodium and semaglutide acetate are different active ingredients from the one used in the approved drugs, that it lacks information on whether they share the same chemical and pharmacologic properties, and that it is not aware of any lawful basis for their use in compounding.

What Preparation Actually Involves

In broad terms, a sterile injectable preparation is compounded under aseptic conditions in a controlled environment. United States Pharmacopeia standards for sterile compounding govern facility design, air quality, personnel technique, beyond-use dating and environmental monitoring, and state boards of pharmacy inspect against them.

The preparation is dispensed against a prescription for a named patient. That patient-specific requirement is what distinguishes lawful compounding from unlicensed production, and it is why any product sold without a prescription is outside the framework entirely.

Quality testing practices vary between pharmacies. Potency and sterility testing are common, but because there is no premarket approval step, the testing regime is a property of the individual pharmacy and its state oversight rather than a nationally standardised requirement.

What Cannot Lawfully Be Compounded

Retatrutide and cagrilintide cannot be used in compounding under federal law. They are not components of FDA-approved drugs and have not been found safe and effective for any condition. The FDA has warned telehealth companies for marketing them, API distributors for selling them to compounders, and outsourcing facilities for repackaging them.

The agency has also documented fraudulent compounded semaglutide and tirzepatide carrying false label information — including labels naming pharmacies that did not compound the product, and in some cases pharmacies that do not exist.

These are not theoretical concerns. The FDA reported one adverse event associated with a product labeled as compounded tirzepatide from a pharmacy that had not actually compounded it, with redness, swelling, pain and a lump at the injection site.

The Documented Safety Signals

As of May 31, 2026 the FDA reported receiving 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency notes that state-licensed pharmacies which are not outsourcing facilities are not required by federal law to submit adverse event reports, so these are likely undercounts.

Many of the reported events appear consistent with adverse events seen with the approved products. A distinct subset relates to dosing errors — patients measuring and self-administering incorrect doses, clinicians miscalculating doses, and prescriptions written beyond what appears in the approved label.

Shipping is a third signal. The FDA has received complaints of compounded GLP-1 drugs arriving warm or with inadequate ice packs, and recommends that patients not use any injectable GLP-1 drug that arrives warm or with insufficient refrigeration.

What to Ask Before You Accept a Compounded Preparation

Which pharmacy compounded it, and is that pharmacy licensed in your state? Is the base form of semaglutide being used, rather than a salt form? What potency and sterility testing was performed, and can documentation be provided?

How is the intended dose measured and administered, and who do you contact with questions after delivery? The FDA specifically encourages patients to have that conversation with their prescriber or compounder.

And be alert to the agency's listed warning signs: any claim that a compounded drug is the same as an FDA-approved drug, prices that seem too good to be true, damaged packaging, missing instructions for use, label spelling errors, or an incorrect pharmacy address.

How Your Genetics Relate to GLP-1 Pathways

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, FTO rs9939609, and MC4R rs17782313 — relate to the biological pathways these medications act on. These are pathway-level associations only and do not predict how much weight you will lose or how you will respond to any specific medication. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights so you and your provider can see how your genes relate to these pathways. It does not recommend, prescribe, or determine which medication, dose, or peptide is right for you. The PlexusDx Precision Peptide Genetic Test ($298) gives you and your provider pathway-level genetic context to support a more personalized conversation. Genetics is a guide, not a guarantee.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers seven prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection is $189/mo month-to-month, or from $149/mo on the 6-month plan. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $298 to personalize your protocol from day one.

Frequently Asked Questions

Is compounded semaglutide the same as Ozempic or Wegovy?

No. Ozempic and Wegovy are FDA-approved finished products with reviewed labeling and established manufacturing controls. A compounded preparation is prepared by a state-licensed pharmacy against an individual prescription and is not FDA-approved. The agency does not review compounded drugs for safety, effectiveness or quality before marketing, and explicitly distinguishes them from generic drugs.

What is the difference between a 503A pharmacy and a 503B facility?

Section 503A covers traditional pharmacy compounding pursuant to a valid prescription for an identified individual patient, primarily regulated by state boards of pharmacy. Section 503B covers outsourcing facilities, a distinct category registered with the FDA and subject to different obligations. PlexusDx works only with licensed 503A compounding pharmacies.

Why are semaglutide salt forms a problem?

The FDA states that semaglutide sodium and semaglutide acetate are different active ingredients from the one used in the approved drugs. The agency does not have information on whether these salts share the same chemical and pharmacologic properties as the approved active ingredient, and says it is not aware of any lawful basis for their use in compounding.

How many adverse events have been reported for compounded semaglutide?

As of May 31, 2026 the FDA reported receiving 990 adverse event reports associated with compounded semaglutide and more than 730 associated with compounded tirzepatide. The agency notes that federal law does not require state-licensed pharmacies which are not outsourcing facilities to submit adverse event reports, so it considers these numbers likely to be undercounts.

What should I check before accepting a compounded preparation?

Confirm which pharmacy compounded it and that the pharmacy is licensed in your state, that the base form rather than a salt form was used, and what potency and sterility testing was performed. Ask who to contact after delivery. Treat damaged packaging, missing instructions for use, label spelling errors or an incorrect pharmacy address as warning signs.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.